When the Trip Becomes a Treatment Model

1. This Doesn't Look Like Prescribing an SSRI

A psilocybin treatment pathway could involve psychiatric and medical screening, preparation, medication administration, several hours of supervised monitoring, discharge planning, and follow-up.

A single treatment could occupy a room and some amount of clinical staff time for most of the working day.

How is this going to work?

Esketamine already gives psychiatry a preview. Patients receiving Spravato require at least two hours of supervised, direct-observation monitoring, including respiratory monitoring with pulse oximetry, with blood pressure assessed before dosing, again at approximately 40 minutes (its peak concentration), and thereafter as clinically warranted (Spravato [esketamine] prescribing information, 2025). CMS has developed billing mechanisms that recognize not only the drug but also the assessment and monitoring burden surrounding its administration.

Psilocybin could stretch that esketamine model much further.

We are looking at two hours of monitoring versus something closer to six!

How many patients can one clinic realistically treat? How many staff members are required? What does it cost to dedicate a room for most of the day? Can one clinician supervise more than one patient? Who pays for all of that time?

2. Before We Build the Clinic, the Numbers Need a Revisit

The enthusiasm and recent headlines surrounding psilocybin can make its eventual approval feel inevitable. Some trials have produced impressive antidepressant effects, including studies in treatment-resistant depression (TRD). But not all of the 2026 literature has been uniformly positive.

☕️ ☕️ The German EPISODE randomized trial in treatment-resistant major depression did not meet its primary response endpoint at six weeks. Response occurred in 17.0% of patients receiving 25 mg compared with 10.6% receiving active placebo (nicotinamide), although a key secondary endpoint (change in depressive symptom severity) did favor psilocybin (Mertens et al., 2026). Investigators also reported safety findings that deserve attention, including a higher rate of suicidal ideation on dosing days (4% vs 1–2% in comparators) and one case of hallucinogen persisting perception disorder (Mertens et al., 2026).

This brings us back to an important reality: efficacy, safety, patient selection, and durability are still being defined even as the field begins thinking about implementation.

3. How Close Are We?

COMP360, a proprietary synthetic psilocybin formulation being developed for treatment-resistant depression, has advanced through Phase 3 development. In one Phase 3 trial, a single 25 mg dose produced a statistically significant −3.6-point MADRS advantage over placebo at week 6, and a second, larger Phase 3 trial (n = 581) reported a −3.8-point advantage versus a 1 mg control (Guidetti et al., 2026). The regulatory process now makes a potential FDA decision something clinicians and health systems can reasonably begin planning for.

Psilocybin's federal controlled-substance status creates a second regulatory problem. FDA approval and DEA scheduling are separate processes. Even with a successful FDA review, controlled-substance requirements and potential rescheduling could influence when the medication actually reaches patients.

4. We Already Have a Real-World Experiment: Oregon

There is another reason this discussion no longer needs to remain entirely theoretical.

Oregon has created the first statewide regulated psilocybin-services system. In its first full year (2025), 5,935 clients participated in 5,375 sessions, with acute adverse events rare (behavioral and medical rates of 2.42 and 2.79 per 1,000 sessions, respectively) (Yu et al., 2025). While smaller than the interest in psychedelics might suggest, this already represents a supervised-use population larger than the classic-psychedelic clinical-trial experience.

Oregon's system offers a preview of the logistical demands.

Facilitators undergo extensive training. Preparation occurs before administration. Psilocybin is consumed under direct observation at a licensed service center rather than taken home. Clients remain on site during the administration session.

In other words, Oregon demonstrates that psychedelic treatment can be operationalized.

The question isn't simply whether psilocybin can be delivered at scale.

It is whether it can be delivered at scale inside the current medical system.

5. What Would a Medical Psilocybin Clinic Actually Look Like?

Probably not much like the psychiatric offices most of us work in today.

Operationally, psilocybin treatment may resemble a hybrid of esketamine, TMS, infusion medicine, and eventually psychotherapy.

A clinic would require dedicated treatment rooms, comfortable reclining chairs or beds, controlled-substance procedures, emergency protocols, trained monitors, vital-sign monitoring, and enough physical space to accommodate patients for much of the day.

Do these patients pack a lunch? What are they eating and drinking? Do they even have an appetite?

Consider the throughput problem.

A PMHNP or psychiatrist might complete 8, 10, or more traditional medication-management visits during the same period that one patient occupies a psilocybin treatment room.

That does not necessarily mean the prescriber must remain with the patient continuously. It brings up the idea of working to the level of your license. Does someone with that level of expertise need to be in the room the whole time? No. But somebody does.

And that brings us back to the economics: What level of clinician needs to be in that room?

6. Who Actually Provides the Treatment?

This may become one of the most consequential regulatory decisions.

Oregon permits a facilitator model that does not require traditional clinical licensure. Colorado has taken a different approach, incorporating existing licensed healthcare and mental-health professionals into portions of its framework. FDA draft guidance for psychedelic clinical investigations has contemplated trained monitors and emphasized qualifications for those responsible for patient safety.

One possibility is that a specially trained psychedelic-treatment professional provides observation, with the prescribing clinician immediately available when needed.

The eventual FDA labeling, any REMS requirements, DEA rules, state scope-of-practice laws, payer policies, and professional standards will determine which versions are possible.

For PMHNPs, psychiatrists and therapists, this is not a minor workforce question. It may determine whether psilocybin treatment is financially scalable at all vs. it being as complex as setting up a dialysis treatment center.

7. Who Gets It First?

The first medical population is likely to be considerably narrower than the enormous public interest in psychedelics might suggest.

Treatment-resistant depression is the obvious starting point under the current development pathway.

That means screening will matter enormously.

Programs will need protocols addressing bipolar-spectrum illness, psychotic disorders, cardiovascular risk, substance use, suicidality, concomitant medications, previous treatment failures, and whether a particular patient can safely tolerate an intense, altered state of consciousness lasting several hours.

Existing antidepressants present another practical question.

Must they be discontinued? Can patients remain on SSRIs? Do particular medications attenuate the psychedelic experience or therapeutic response? Notably, most confirmatory trials required antidepressant withdrawal before dosing, though an exploratory study suggested feasibility of psilocybin adjunctive to an ongoing SSRI.

These may sound like relatively mundane medication-management questions compared with the neuroscience surrounding psychedelics. In practice, they could determine who actually qualifies for treatment.

8. The Question Nobody Can Ignore: How Long Does the Benefit Last?

The durability of ketamine has been widely discussed. The durability of psilocybin is still being defined.

This may ultimately be just as important as whether psilocybin works initially.

The attraction of the model is obvious: instead of taking an antidepressant every morning for years, could a patient receive one or several intensive treatments and experience improvement lasting months?

Possibly. The longest systematic follow-up to date — a 12-month naturalistic follow-up of the EPISODE phase 2b TRD trial — found a stable, clinically meaningful antidepressant effect at both 6 and 12 months. Importantly, there were no between-group differences at follow-up, because all study arms had eventually received a 25 mg dose, so the design cannot isolate durability against an untreated comparator (Mertens et al., 2026, Psychotherapy and Psychosomatics). Re-initiation of antidepressants during follow-up was associated with higher depression scores. Controlled, long-term durability data against an active comparator remain limited.

That raises an enormously important practical question: What if psychedelic treatment eventually requires maintenance?

One six-hour appointment is an unusual healthcare delivery problem. Six-hour appointments repeated periodically are an entirely different economic model.

If patients require booster sessions every few months or some other maintenance strategy, then capacity calculations change dramatically. The long-term economics of psilocybin therefore depend not simply on response rates but on durability per treatment day.

9. Esketamine Gives Us a Warning About Reimbursement

Esketamine is FDA approved, administered under a REMS program, and requires supervised observation. Medicare created dedicated codes that recognize the clinical assessment and monitoring surrounding administration.

That is encouraging because it establishes an important precedent: payers can reimburse the infrastructure surrounding a psychiatric medication rather than paying only for the molecule.

But esketamine also illustrates the problem. Even with roughly two-hour monitoring periods and an established reimbursement structure, its economics and cost-effectiveness have been debated.

Now imagine extending the treatment-room requirement from approximately two hours toward six.

Psilocybin could require fewer total administrations than esketamine, which would substantially change the equation. But whether that advantage survives depends heavily on durability.

Treatment effect × durability ÷ staff time and treatment-room time.

The clinical winner may ultimately be the intervention that produces the most sustained improvement per hour of psychiatric infrastructure.

10. The Biggest Barriers

Suppose psilocybin receives FDA approval and produces clinically meaningful outcomes in appropriately selected patients. Psychiatry would still have to solve a formidable implementation problem:

Most psychiatric practices were not designed for this. Even successful interventional psychiatry programs were largely built around shorter encounters.

11. Forecast

2026: Phase 3/regulatory-submission era. Specialty practices and health systems begin seriously modeling implementation.

2027: Earliest plausible FDA approval and commercial launch, contingent on successful regulatory review and resolution of controlled-substance requirements.

2027–2029: Early adoption concentrated in academic medical centers, psychedelic specialty programs, and established interventional psychiatry practices already comfortable with esketamine, TMS, or infusion treatments.

2029–2032: Real-world effectiveness, durability, repeat-treatment requirements, reimbursement models, staffing protocols, and patient-selection standards become clearer.

The timeline could move substantially in either direction.

☕☕ Eva’s Take

If you’re building your practice or deciding where to spend your continuing-education dollars, I wouldn’t invest heavily in psilocybin training just yet.

There are simply too many variables still on the table: FDA approval, DEA scheduling, staffing, supervision, reimbursement, patient selection, durability, and the economics of tying up a treatment room for much of the day. Right now, the math ain’t mathing yet.

For now, I’d invest those education dollars in skills you can bring back to your practice Monday morning: psychopharmacology, trauma, psychotherapy, sleep, or integrative psychiatry—areas that can add value to the patients already sitting across from us.

Psilocybin? Keep watching. We’ll be following it closely at Eva’s Tea.

Selected References

Guidetti, C., Fava, M., & Papakostas, G. I. (2026). Novel approaches in depression treatment: From rapid-acting antidepressants to personalized interventions. Molecular Psychiatry. Advance online publication.

Janssen Pharmaceuticals. (2025). Spravato (esketamine) prescribing information. U.S. Food and Drug Administration.

Mertens, L. J., Koslowski, M., Betzler, F., et al. (2026). Efficacy and safety of psilocybin in treatment-resistant major depression: The EPISODE randomized clinical trial. JAMA Psychiatry. Advance online publication.

Mertens, L. J., Betzler, F., Brand, M., et al. (2026). Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant major depression: 6- and 12-month naturalistic follow-up of a phase 2b trial. Psychotherapy and Psychosomatics. Advance online publication.

Yu, F., Tafur, J., Moreno, F., & Dahmer, S. (2025). Inaugural year of regulated psilocybin services in Oregon: Safety, motivations, and utilization. Frontiers in Psychiatry, 16.